Here are the 8-K filings from TCGX Acquisition Corp. (TCGX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow TCGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCGX filings page.
TCGX Acquisition Corp. agreed to combine with TriGemX Bio, Inc., with closing expected in the first quarter of 2027, subject to shareholder approvals and other conditions. At closing, PIPE investors would buy 16,000,000 shares of New TriGemX common stock at $10.00 per share for $160 million in gross proceeds, subject to subscription conditions. Assuming no TCGX public-shareholder redemptions, total gross proceeds are expected to be approximately $246 million, including approximately $86 million from TCGX’s trust; expected post-transaction equity value is approximately $600 million.
TriGemX stockholders would exchange their shares for New TriGemX stock and roll 100% of their equity, without cash proceeds; TCGX Class A shareholders may redeem shares for their pro rata portion of trust funds. TriGemX’s agreed pre-money equity value is $361 million; the exchange ratio is based on that value, a $10.00 per-share New TriGemX value and TriGemX’s fully diluted share count. TriGemX’s obligation to close also requires at least $150 million in Available Closing Cash. TriGemX stated that approximately $111 million in cash as of October 1, 2026, funds operations into Q3 2027. Before the merger, TCGX is to domesticate in Delaware and change its name to TriGemX Bio, Inc.